NASDAQ:QDELQuidel Stock Price, Forecast & News

$93.69

+6.13 (+7.00 %)

(As of 04/8/2020 04:00 PM ET)

Add

Compare

Today's Range

$86.30

Now: $93.69▼

$95.23

50-Day Range

$74.20

MA: $85.17▼

$103.64

52-Week Range

$52.49

Now: $93.69▼

$106.56

Volume702,530 shs

Average Volume456,395 shs

Market Capitalization$3.92 billion

P/E Ratio54.47

Dividend YieldN/A

Beta0.71

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

1.3 Analyst's Opinion

Consensus Rating
Quidel has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $83.00, Quidel has a potential downside of 11.4% from its current price of $93.69.
Amount of Analyst Coverage
Quidel has only been the subject of 2 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Quidel has received 394 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Quidel has received 352 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Quidel has received 52.82% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote “Outperform” if you believe QDEL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Quidel does not currently pay a dividend.
Dividend Growth
Quidel does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quidel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,002,788.00 in company stock.
Percentage Held by Insiders
Only 14.10% of the stock of Quidel is held by insiders.
Percentage Held by Institutions
91.67% of the stock of Quidel is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Quidel are expected to decrease by -100.00% in the coming year, from $2.90 to $0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Quidel is 54.47, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 12.25.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quidel is 54.47, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.91.
Price to Book Value per Share Ratio
Quidel has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.97 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryHealth Care Supplies

SectorMedical

Current SymbolNASDAQ:QDEL

Previous Symbol

CUSIP74838J10

CIK353569

Webhttp://www.quidel.com/

Phone858-552-1100

Debt

Debt-to-Equity Ratio0.17

Current Ratio1.77

Quick Ratio1.30

Price-To-Earnings

Trailing P/E Ratio54.47

Forward P/E Ratio32.31

P/E GrowthN/A

Sales & Book Value

Annual Sales$534.89 million

Price / Sales7.34

Cash Flow$4.24 per share

Price / Cash Flow22.11

Book Value$13.44 per share

Price / Book6.97

Profitability

EPS (Most Recent Fiscal Year)$2.73

Net Income$72.92 million

Net Margins13.63%

Return on Equity22.71%

Return on Assets13.28%

Miscellaneous

Employees1,250

Outstanding Shares41,880,000

Market Cap$3.92 billion

Next Earnings Date5/13/2020 (Estimated)

OptionableOptionable

Receive QDEL News and Ratings via Email

Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.

Quidel (NASDAQ:QDEL) Frequently Asked Questions

How has Quidel's stock been impacted by COVID-19 (Coronavirus)?

Quidel's stock was trading at $89.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, QDEL shares have increased by 4.5% and is now trading at $93.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Quidel?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Quidel.

When is Quidel's next earnings date?

Quidel is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Quidel.

How were Quidel's earnings last quarter?

Quidel Co. (NASDAQ:QDEL) released its quarterly earnings results on Wednesday, February, 12th. The company reported $1.00 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.82 by $0.18. The business had revenue of $152.20 million for the quarter, compared to analysts' expectations of $148 million. Quidel had a net margin of 13.63% and a return on equity of 22.71%. Quidel's revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.80 EPS. View Quidel's earnings history.

What guidance has Quidel issued on next quarter's earnings?

Quidel issued an update on its fourth quarter 2019 After-Hours earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $151-152 million, compared to the consensus revenue estimate of $139.17 million.

What price target have analysts set for QDEL?

4 brokers have issued twelve-month target prices for Quidel's shares. Their forecasts range from $75.00 to $92.00. On average, they anticipate Quidel's stock price to reach $83.00 in the next twelve months. This suggests that the stock has a possible downside of 11.4%. View analysts' price targets for Quidel.

Has Quidel been receiving favorable news coverage?

Media coverage about QDEL stock has trended very negative this week, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Quidel earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutQuidel.

Are investors shorting Quidel?

Quidel saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,636,200 shares, an increase of 11.3% from the February 27th total of 1,470,000 shares. Based on an average daily volume of 350,200 shares, the days-to-cover ratio is presently 4.7 days. Approximately 4.4% of the shares of the company are sold short. View Quidel's Current Options Chain.

Who are some of Quidel's key competitors?

Some companies that are related to Quidel include Cooper Companies (COO), Align Technology (ALGN), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Antares Pharma (ATRS), Anika Therapeutics (ANIK) and Meridian Bioscience (VIVO).

What other stocks do shareholders of Quidel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quidel investors own include Netflix (NFLX), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), AT&T (T), Cisco Systems (CSCO), Adobe (ADBE), Gilead Sciences (GILD), Target (TGT) and Intel (INTC).

Who are Quidel's key executives?

Quidel's management team includes the following people:

Mr. Douglas C. Bryant, Pres, CEO & Director (Age 61)
Mr. Randall J. Steward, Chief Financial Officer (Age 65)
Mr. Robert J. Bujarski, Sr. VP of Bus. Devel. & Gen. Counsel (Age 51)
Dr. Werner Kroll, Sr. VP of R&D (Age 62)
Mr. Edward Keith Russell, Sr. VP of Global Commercial Operations (Age 51)

What is Quidel's stock symbol?

Quidel trades on the NASDAQ under the ticker symbol "QDEL."

How do I buy shares of Quidel?

Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quidel's stock price today?

One share of QDEL stock can currently be purchased for approximately $93.69.

How big of a company is Quidel?

Quidel has a market capitalization of $3.92 billion and generates $534.89 million in revenue each year. The company earns $72.92 million in net income (profit) each year or $2.73 on an earnings per share basis. Quidel employs 1,250 workers across the globe. View additional information about Quidel.

What is Quidel's official website?

The official website for Quidel is http://www.quidel.com/.

How can I contact Quidel?

Quidel's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 858-552-1100 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: What is the FTSE 100 index?

NASDAQ:QDELQuidel Stock Price, Forecast & News

Adding

Adding

Adding Quidel Co.

Beat the Market (BTM) Rank™

1.3 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage